Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02763215 · ClinicalTrials.gov registry record
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
A clinical trial of Wilson Disease, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- 64
- Enrollment target
- 10
- Study locations
NCT02763215 is a study of Wilson Disease that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 64 participants, below the 111-participant average among 4 other Wilson Disease trials with a reported enrollment target (42% lower). The trial reports 10 study locations across 6 states.
The verdict
NCT02763215, a study of Wilson Disease, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
- 10
- Study locations
Study Summary
This was a 24-month study to assess copper parameters in participants with Wilson disease (WD) treated with standard of care (SoC) medications. After providing informed consent, participants meeting all inclusion and no exclusion criteria were enrolled into the study as outpatients. The participants' routine clinic visits were scheduled according to the standard clinical practice at the study center and at the discretion of the treating physician at approximate 6-month intervals. At the time of enrollment, participants were receiving SoC medications for the treatment of WD, which could include penicillamine, trientine, zinc, or a combination of a copper chelator and zinc. If treatment was interrupted or stopped during the course of the study, participants continued in the study and biological samples and clinical data were continued to be collected for the full 24-month study period. Dosing with SoC agents was individualized and managed by the treating physician at the study center according to standard clinical practice at the site.
Conditions Studied
Interventions
- DRUG Standard of Care Medications
Study Locations (10)
Other
- Clinical Trial Site - Vienna
- Clinical Trial Site - Heidelberg
- Clinical Trial Site - Warsaw
- Clinical Trial Site - Birmingham
- Clinical Trial Site - Guildford
Connecticut
- Clinical Trial Site - New Haven
Illinois
- Clinical Trial Site - Chicago
Michigan
- Clinical Trial Site - Ann Arbor
Tennessee
- Clinical Trial Site - Nashville
Washington
- Clinical Trial Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2016-05-19 |
| Est. Completion | 2019-01-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02763215
The ClinicalTrials.gov registry entry for NCT02763215 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 111-participant average among 4 other Wilson Disease trials with a reported enrollment target (42% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Wilson Disease appearing as the primary indexed condition, and to 1 intervention - of which Standard of Care Medications is the first listed.
NCT02763215 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Other, Connecticut, Illinois.
Frequently Asked Questions
What is clinical trial NCT02763215 about?
NCT02763215 is a clinical study titled "The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment". This was a 24-month study to assess copper parameters in participants with Wilson disease (WD) treated with standard of care (SoC) medications. After providing informed consent, participants meeting all inclusion and no exclusion criteria were enrolled into the study as outpatients. The participant...
What is the current status of trial NCT02763215?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2016-05-19. Estimated completion is 2019-01-21.
What conditions does trial NCT02763215 study?
This clinical trial studies the following conditions: Wilson Disease.
What interventions are being tested in trial NCT02763215?
The interventions under investigation include: Standard of Care Medications (DRUG).
Who is sponsoring clinical trial NCT02763215?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02763215 being conducted?
This trial has 10 study locations across Connecticut, Illinois, Michigan, Tennessee, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wilson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial
RECRUITING
-
Natural History of Wilson Disease
RECRUITING
-
Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study
RECRUITING
-
A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.